Epidemiology and microbiology of Shiga toxin-producing Escherichia coli other than serogroup O157 in England, 2009England, -2013 
INTRODUCTION
Shiga toxin-producing Escherichia coli (STEC), also known as verocytotoxin-producing E. coli (VTEC), is defined by the presence of the stx genes (stx1, stx2 or both). There are more than 400 different serotypes of STEC and over 100 of these are known to cause symptoms of gastrointestinal (GI) disease in humans, including severe bloody diarrhoea and haemolytic uraemic syndrome (HUS) (Scheutz & Strockbine, 2005) . Previous studies have indicated that the presence of stx2, specifically the stx2a subtype, is more frequently associated with severe disease (Ethelberg et al., 2004; Persson et al., 2007; Luna-Gierke et al., 2014) . Many STEC associated with human disease also have the intimin-encoding gene eae (E. coli attaching and effacing), located on a pathogenicity island called the locus of enterocyte effacement (LEE), and associated with the intimate attachment of the bacteria to the human gut mucosa (Frankel et al., 2001) . Recently, strains of STEC that do not have the eae gene but carry a plasmid encoding aggR, associated with the enteroaggregative E. coli group, have also been associated with causing HUS (Frank et al., 2011; Dallman et al., 2012) .
In England, national protocols for the detection of STEC are specific for STEC serogroup O157 and focus on the isolation on selective media of non-sorbitol fermenting colonies of E. coli agglutinating with antisera to the O157 antigen (http:// www.hpa.org.uk/ProductsServices/MicrobiologyPathology/ UKStandardsForMicrobiologyInvestigations/TermsOfUseForSMIs/ AccessToUKSMIs/SMIBacteriology/smiB30InvestigationofFaecal SpecimensforEnteric/). For cases of severe disease consistent with STEC infection where O157 is not isolated at the frontline hospital laboratory, it is recommended that faecal specimens are referred to the Gastrointestinal Bacteria Reference Unit (GBRU) for re-testing for the presence of both O157 and non-O157 STEC [Public Health England (PHE) STEC Operational Guidelines, http://www.hpa.org. uk/webc/HPAwebFile/HPAweb_C/1279889252950]. Over the last 10 years, approximately 15-20 isolates of non-O157 STEC (around 1.5 % of all STEC) were identified annually from faecal specimens referred to the GBRU using PCR and culture . In other countries, non-O157 STEC have been identified as a significant cause of GI disease, including HUS, and their incidence may exceed that of STEC O157 (Tozzi et al., 2003; Gould et al., 2013; Preußel et al., 2013) . However, in England the bias towards detection of non-O157 STEC from patients with severe disease only, means that the true incidence and pathogenic potential of non-O157 STEC is unknown.
Between December 2012 and December 2013, three frontline hospital laboratories in England implemented commercial PCR assays targeting GI pathogens, including STEC, as a first-line diagnostic detection method (referred to as GI PCR). All faecal specimens submitted to the three frontline laboratories were tested regardless of the patient's age or symptoms. One laboratory used the assay throughout 2013 (12 months of the study period), while the other two laboratories implemented the assay in November 2013 (2 months of the study period). Two laboratories used the EntericBio assay and one used the BD Max assay. An increasing number of laboratories in England report plans to adopt a PCR approach in 2014 (GBRU in-house data).
This move towards a more sensitive and comprehensive molecular approach to GI-pathogen diagnostics has had a significant impact on the detection of non-O157 STEC and led to an increase in the number of faecal specimens referred to the GBRU. Consequently, there has been an increase in the number of strains of non-O157 STEC detected. The aim of this report is to describe the characteristics of non-O157 strains detected between 2009 and 2013, and to examine their pathogenicity traits alongside the available epidemiological data.
METHODS
Microbiological characterization. Faecal specimens from patients suspected of having STEC infection (those with symptoms of HUS and severe bloody diarrhoea) that were culture negative for STEC O157, and more recently those specimens testing positive for the stx genes using commercial GI-pathogen PCR assays (GI PCR), were submitted to the GBRU for further testing (referred to as GBRU PCR) (Table 1) . Briefly, DNA extracted from faecal culture broths was tested using a real-time PCR targeting stx1, stx2, eae (intimin) and O157 rfbE according to the method of the EU Reference Laboratory for E. coli . For faecal specimens positive for stx, 20 colonies were picked from bacterial growth on MacConkey or sorbitol MacConkey agar plates and re-tested using the same PCR. Those colonies harbouring the stx genes were identified biochemically as E. coli using appropriate sugars and other metabolites in glass tubes. Positive reactions were observed by noting a change in the colour of the media, and profiles were analysed as described by Scheutz & Strockbine (2005) . Strains were serotyped using antisera raised in rabbits to the E. coli somatic O antigens (Gross & Rowe, 1985) . Each isolate was further characterized using additional PCRs targeting aggR (http://www.iss.it/ binary/vtec/cont/Geraldine_Smith.pdf) and the stx2 subtyping genes (Scheutz et al., 2012) .
Epidemiology. Local laboratories report presumptive isolates of STEC directly to PHE Centres (PHECs). Each PHEC arranges for a standard enhanced surveillance questionnaire (ESQ) to be administered to patients in a timely manner as part of routine public health followup. The ESQ collects data in the following categories: demographic details; risk status; clinical condition (including progression to HUS); Table 1 . Overview of the process of isolating non-O157 STEC in the GBRU from referred faecal specimens from frontline laboratories Frontline laboratories not using GI PCR Frontline laboratories using GI PCR* Send faecal specimen to the GBRU if:
At the frontline hospital laboratory
Symptoms indicate STEC infection (HUS and/or bloody diarrhoea) and stool culture negative for E. coli O157 Symptoms indicate STEC infection (HUS and/or bloody diarrhoea) and stool culture negative for E. coli O157 or faecal specimen PCR positive for stx genes At the GBRU GBRU PCR for stx1, stx2, eae, O157rfbE genes on faecal enrichment culturesD and 10-20 colonies isolated on the agar plates; stx positive isolates are identified biochemically as E. coli and serotyped (O antigen with rabbit antisera), and virulence typing by PCR for aggR and stx2 subtypes is performed *Two frontline laboratories used the EntericBio Realtime Gastro Panel 1 commercial assay and one used the BD MAX Enteric Bacterial Panel commercial assay. Both methods include a kit-based DNA extraction protocol, and DNA was extracted directly from the faecal specimen. All faecal specimens submitted to the three frontline laboratories were tested regardless of patient's age or symptoms. DPCR performed as previously described by Jenkins et al. (2012) .
household or other close contact details; exposures including travel, food and water consumption, contact with animals and environmental factors; case classification; and outbreak status. Completed questionnaires are forwarded for inclusion in the National Enhanced STEC Surveillance System (NESSS), which is managed by the PHE Gastrointestinal, Emerging and Zoonotic Infections Department (GEZI).
Epidemiological case definitions. A primary case was defined as follows: a symptomatic case with no history of close contact with a confirmed case in the 7 days prior to onset of illness. A secondary case was defined as follows: a case with a date of onset that is more than 4 days after the primary case or where transmission is believed to be through exposure to a primary case. An asymptomatic case was defined as follows: a person identified through contact screening procedures, with no symptoms consistent with STEC infection.
Data analyses. Comparisons were made between groups and Fisher's exact test was used to assess statistical significance. MantelHaenzel odds ratios (ORs) were calculated to assess the relative risk of developing HUS for different groups. A matched case-control analysis was undertaken to test the hypothesis that there were no differences in risk exposures between O157 and non-O157 STEC cases reported over the period 1 January 2009 to 31 December 2013. Cases were matched to controls on the basis of age, gender and PHE region. A matched design was chosen to control for both the different testing methods at different laboratories (the laboratories using PCR over the study period were in the south of England serving two PHE regions) and any differences in behaviour that may be associated with different age groups and genders. Univariable conditional logistic regression was performed to assess for statistically significant differences between the two groups. Exposure variables at a significance level of ¡0.2 were included in a multivariable model. Multivariable conditional logistic regression was performed using a step-wise procedure and likelihood ratio tests undertaken to assess best fit for the model. For all tests a P value of ¡0.05 was deemed statistically significant. All statistical analyses were performed using STATA version 12.0 software (Stata Corps, Texas).
RESULTS

Non-O157 serogroups
Between 1 January 2009 and 31 December 2013, a total of 97 non-O157 STEC isolates from 84 cases were reported in England, representing 34 different E. coli serotypes (Table  2) . This compared with 4330 cases of STEC O157 infection reported during the same period. The most common non-O157 STEC serogroup detected was serogroup O26 with 21 isolates (21.6 %). There were six strains of STEC O104 from cases epidemiologically linked to the outbreak in Germany in 2011 (Frank et al., 2011) . Four isolates of STEC O145 (two cases reported recent travel to Ireland, one had travelled to Egypt and one had not travelled abroad in the exposure period) were reported and there were three isolates of STEC O117 associated with travellers returning from exotic locations, as described previously (Dallman et al., 2013) . Seventeen isolates did not agglutinate with any of the antisera in the serotyping scheme raised to the known E. coli serogroups and were designated 'O unidentifiable'; seven did not express the O antigen, and therefore could not be serotyped; these were designated 'rough'.
Three frontline hospital laboratories implemented the GI PCR approach during the study period: one in December 2012 and two in November 2013. This resulted in a significant increase in the detection of non-O157 STEC (P,0.001). In 2013, 42 (42.4 %) non-O157 STEC isolates were detected compared with a total of 57 in the preceding 4 years (2009) (2010) (2011) (2012) . In total, 22 cases were detected by the three frontline laboratories using GI PCR. One hospital laboratory in London, the region with the lowest STEC incidence in England, reported 19 confirmed non-O157 cases during the first 12 months of adopting the GI PCR approach, while only 5 STEC O157 isolates were reported over that same period. This laboratory had previously reported just three non-O157 cases between 2004 and 2012 (GBRU in-house data). The other two laboratories used GI PCR for only 2 months during the study period and reported no STEC O157 isolates during that time.
Virulence traits and clinical symptoms
Three-quarters of non-O157 isolates (73/97) carried stx2: 45 (46.4 %) had stx2 only, 28 (28.3 %) carried stx1 and stx2, and the remaining 24 (24.2 %) harboured stx1 only ( Table  2 ). The most frequently detected stx2 subtype was stx2a (63.0 %, n546 isolates). Forty isolates carried stx2a only, including the six STEC O104 isolates linked to the outbreak in Germany in 2011 and six STEC O26 isolates. stx2b only was detected in 14 isolates (Table 2) . Other subtypes were rare, including one isolate that had stx2d only and two harbouring stx2g only ( Table 2 ). The nine isolates that were originally positive by GBRU PCR for stx2 tested negative with the stx2 subtyping PCR in this study. On repeat testing using the GBRU PCR, these strains tested negative for stx2 and it is likely that they had lost the stxencoding phage during storage. The eae gene was detected in 50 (51.5 %) non-O157 STEC isolates (Table 2) . Six strains of STEC O104 had aggR; however, aggR was not detected in any other strains in this study.
The 97 non-O157 STEC isolates were associated with 84 individual cases reported to the NESSS. Three cases had multiple serotypes of non-O157 STEC, including one case reporting travel to Egypt infected with both serogroups O145 and O26, one with serogroup O117 and a rough isolate, and one case with serogroups O26, O45 and O91. Nine isolates were from patients enrolled in a large study of infectious intestinal disease (Tam et al., 2012) and were not reported through the NESSS.
Just over half (n546, 54.8 %) of cases were female and almost a third (n530, 35.7 %) were children aged under 15 years. The same gender difference was reported amongst STEC O157 cases (55.2 %), but a higher proportion (42.5 %) of children was observed with STEC O157 infection. For four cases, ESQs were lost to follow-up, and an additional six cases (screened because they were contacts of symptomatic cases) had asymptomatic infection. Among the 74 remaining cases (69 primary and 5 secondary), diarrhoea was reported in 66 (89.2 %) cases, including bloody diarrhoea in 35 There was no significant difference (OR 1.14, P50.800) in development of HUS by gender.
The development of HUS was significantly associated with non-O157 STEC strains possessing eae (OR 5.845, P50.0235) and/or stx2a (OR 9.56, P50.0034) subtypes, when compared with all other strains. All 18 HUS cases (24 isolates) were infected with at least one strain of non-O157 STEC carrying stx2, and most strains (n519, 86.4 %) possessed the stx2a subtype (Table 3 ) and encoded intimin. Two cases that developed HUS had multiple non-O157 STEC serotypes detected. The first had STEC serotypes O26, O45 and O91. Although it is not possible to determine whether one strain was more significant in the progression to HUS for this case, both STEC O26 and O91 harboured stx2a and eae whereas the STEC O45 strain was stx2a and eae negative. The other case had STEC O26, harbouring eae and stx2a, and STEC O145 carrying eae and stx2a.
Unsurprisingly, disease was more severe among STEC cases identified by referral of the faecal specimen to the GBRU following the STEC guidelines (i.e. recommending referral of cases with HUS and bloody diarrhoea) than in those initially detected through the routine testing of all faecal specimens (regardless of severity of symptoms) at the frontline laboratory by PCR. A significantly smaller proportion of cases detected by PCR had strains encoding stx2a (P50.001) and only one-third of strains detected by PCR had eae compared with two-thirds of those referred to the GBRU following the STEC guidelines (P50.01). Among 22 cases detected by PCR, 3 reported bloody diarrhoea and 2 were hospitalized. None of the cases detected by PCR developed HUS.
Non-O157 STEC risk exposures
A matched case-control analysis was undertaken to compare reported risk exposures amongst 69 primary, symptomatic, non-O157 STEC cases and 2300 primary STEC O157 cases. The final multivariable model indicated significantly increased odds among non-O157 STEC cases of contact with farm animals, including cattle, sheep, pigs, goats, horses and poultry (Table 4) . Contact with farm animals included visiting petting farms, living on or having access to a farm and incidental contact in the countryside. Cases of STEC O157 had greater odds than non-O157 STEC cases of freshwater swimming, handling or consuming raw beef and shopping at independent retailers, including butchers, grocers, delicatessens and markets.
DISCUSSION
The implementation of GI PCR at just one frontline laboratory, for the greater part of the year, significantly increased the detection of non-O157 STEC cases in England. Notably, almost four times as many non-O157 isolates than O157 isolates were detected at that laboratory during that time, indicating the extent to which non-O157 STEC is under-ascertained through traditional culture methods. Although the numbers in this study were low in comparison with STEC O157 cases, collection of clinical data through the NESSS coupled with strain characterization, including detection of genes associated with adherence to the gut mucosa and stx2 subtyping, facilitated the assessment of virulence traits belonging to different strains of non-O157 STEC.
Elsewhere in Europe, STEC serogroups O26, O103, O111 and O145, along with STEC O157, are regarded as the most common STEC serogroups associated with severe disease and outbreaks (Gerber et al., 2002; Beutin et al., 2004; Brooks et al., 2005; Carroll et al., 2005) . While all four of these non-O157 STEC serogroups were identified in this dataset, with STEC O26 being the most common (Jenkins et al., 2008; Chase-Topping et al., 2012; Bielaszewska et al., 2013) , a variety of other serogroups were also found. The wide range of serogroups and the fact that 24 % of the strains could not be serogrouped (strains designated rough and unidentifiable) using the current serotyping scheme suggests that reliance on serogroup alone to indicate pathogenicity would be misleading. Non-O157 STEC in England 2009 -2013 Furthermore, non-O157 STEC are a heterogeneous group, and the ability of specific serogroups to cause severe illness in humans is likely to be determined by toxin subtype and additional attachment genes involved in pathogenesis.
As described in other studies, intimin and stx2a subtypes were all significantly associated with progression to HUS (Gerber et al., 2002; Beutin et al., 2004; Brooks et al., 2005; Ethelberg et al., 2004; Persson et al., 2007; Luna-Gierke et al., 2014) . It is important to note, however, that not all cases of HUS in this study were infected with strains exhibiting these properties. Other bacterial virulence traits, such as aggR, are associated with HUS, and human host factors, such as age, may also impact on the likelihood of disease progression. It is well documented that children are at greater risk of developing STEC-HUS, and our findings were consistent with this (Lynn et al., 2005) . There are also likely to be additional, as yet unproven, bacteria and host factors associated with disease progression.
Examination of reported risk exposures among non-O157 STEC cases revealed significantly increased reporting of farm animals as compared with O157 cases, while reporting of freshwater swimming (i.e. in rivers and lakes), shopping at independent retailers and handling or consuming raw beef was less likely. However, it is difficult to draw conclusions from these data as the numbers of non-O157 STEC in this study are low and because the non-O157 STEC are a heterogeneous group. Furthermore, the sensitivity of the ESQ is limited to the risk exposures included on the questionnaire, and is subject to both interviewer and recall biases. Isolation and confirmation of non-O157 STEC by the GBRU takes longer than confirmation of STEC O157, and notification to PHE health protection teams and subsequent public health follow-up, including administering the ESQ, is delayed in comparison. Thus, for non-O157 STEC, epidemiological data may be less reliable due to the time-lag affecting patient recall. The introduction of PCR at the frontline offers an opportunity to reduce this lag and subsequent recall bias if public health follow-up can be taken on the basis of PCR detection at the frontline.
Direct testing of all faecal specimens and the subsequent increase in the number of STEC cases raised questions regarding the clinical and public health impact of non-O157 STEC in England. The clinical symptoms, and therefore the public health significance, of non-O157 STEC cases in this study were severe, with a considerably higher proportion of cases developing HUS than observed for STEC O157. However, these data are biased by selective referral of specimens to the GBRU from cases with severe disease. Moving forward, cases identified at the frontline laboratories by direct testing of all faecal specimens using the GI PCR approach will readdress this bias. Widespread implementation of the GI PCR approach, and subsequent follow-up via the NESSS, will enhance our ability to determine the true incidence of non-O157 STEC infection, the burden in terms of morbidity and mortality, and whether there are niche risk exposures for particular strains. *Excludes nine isolates detected in the infectious intestinal disease II study (Tam et al., 2012) as these clinical data are unavailable.
DTwo HUS cases had multiple strains of non-O157 isolated. 
